This week I'm posting an interview that I had with Dr. Anthony Mato from U Penn when we talked at ASH 2016 about the real-world research he has been doing patients being treated with ibrutinib both in the community and academic settings, and not just within clinical trials. You can view my summary, watch the interview or read the transcript here: cllsociety.org/2017/05/ash-...
The data suggests that in the community it is intolerance and side effects that is the most common reason for stopping a signal blocker such as ibrutinib. Disease progression is a distant second.
This is important because these drugs are game changing and finding ways to maximize their benefit is critical.
We are all in this together.